Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study

Otlu, Baris; AÇIKGÖZ, Nusret; ATAŞ, Halil; ERMİŞ, Necip; YAĞMUR, Jülide; CANSEL, MEHMET; TOPAL, Ergün

Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study

Ergün TOPAL, (Özel Müjde Hastanesi, Malatya, Türkiye)

Jülide YAĞMUR, (İnönü Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye)

Barış OTLU, (İnönü Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Malatya, Türkiye)

Halil ATAŞ, (İnönü Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye)

Mehmet CANSEL, (İnönü Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye)

Nusret AÇIKGÖZ, (İnönü Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye)

Necip ERMİŞ (İnönü Üniversitesi, Tıp Fakültesi, Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye)

Anadolu Kardiyoloji Dergisi

7 0

Yıl: 2012 Cilt: 12 Sayı: 2 Sayfa Aralığı: 115 - 120 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study

Öz:

Amaç: Urocortin (Ucn) hormonları kardiyovasküler sistemde önemli rol oynamaktadır. Sistolik işlev bozukluğu (SD) dışında, diyastolik işlev bozukluğu (DD) veya koroner arter hastalığının (KAH) serum Ucn-2 ile ilişkisine dair yeterli veri bulunmamaktadır. Bu çalışmamızda SD, DD ve KAH’da serum Ucn-2 düzeyini araştırdık. Yöntemler: Bir gözlemsel enine-kesitli olan bu çalışmanın popülasyonu KAH ön tanısı ile koroner anjiyografi işlemine alınan bireyler arasından belirlendi. Koroner anjiyografi sonrası ekokardiyografi yapılarak 86 kişi seçildi. Ucn-2 ile SD arasındaki ilişkiyi araştırmak için ejeksiyon fraksiyonu (EF) farklı üç grup oluşturuldu: orta-ileri düzey SD olanlar (Grup A, EF=%33.6), hafif-orta SD olanlar (Grup B, EF=%46.1) ve SD olmayanlar (Grup C, EF= %64.5). Ayrıca, DD sahip olan ve olmayanlar (EF≥ %45) arasında ve KAH’ı olan ve olmayanlar (EF≥ %55) arasında da Ucn-2 düzeyi karşılaştırıl- dı. İstatistiksel analizde tek yönlü ANOVA, Kruskal-Wallis, Ki-kare, Mann-Whitney U, Spearman korelasyon ve çoklu regresyon testleri kullanıldı. Bulgular: Grup C’ye göre, Ucn-2 düzeyinin Grup A’da azaldığı ve Grup B’de arttığı saptandı (Grup A, B ve C’de sırasıyla Ucn-2; 9.4±3.4, 12.8±3.6 ve 10.4±3.9 pg/mL, p=0.003). SD’den farklı olarak; Ucn-2 düzeyi bakımından, DD olan ve olmayanlar arasında (11.4±4.1 ve 11.7±3.9 pg/mL, p=0.8) veya KAH olan ve olmayanlar arasında (10.7±4.7 ve 10.2±3.2 pg/mL, p=0.7) anlamlı bir fark saptanmadı. Sonuç: Serum Ucn-2 düzeyi hafif-orta sistolik disfonksiyonda yükselmektedir. Ancak, DD (azalmış gevşeme bozukluğu) veya KAH’ın (miyokart enfarktüsü olmadan) serum Ucn-2 düzeyini etkilemediği görülmektedir.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Ürocortin-2 ile sistolik, diyastolik fonksiyonlar ve koroner arter hastalığının ilişkisi: Gözlemsel bir çalışma

Öz:

Objective: The urocortin (Ucn) hormones have many important roles in the cardiovascular system. Apart from systolic dysfunction (SD), there is no sufficient data on the relationship between serum Ucn-2 and diastolic dysfunction (DD), or coronary artery disease (CAD). We investi- gated serum Ucn-2 levels in SD, DD, and CAD. Methods: In this observational cross-sectional study, study population was enrolled among outpatients who underwent coronary angiography with the pre-diagnosis of CAD. By examining the echocardiography 86 subjects were selected to study after coronary angiography. The subjects distributed over three groups to investigate the relationship between serum Ucn-2 and SD according to their ejection fraction (EF): subjects with moderate to severe SD (Group A, EF=33.6%), subjects with mild to moderate SD (Group B, EF=46.1%), and those without SD (Group C, EF=64.5%). Apart from these groups, the serum Ucn-2 levels were compared between subjects with and without DD (EF≥45%), and also com- pared between subjects with and without CAD (EF≥55%). Statistical analyses were performed using one-way ANOVA, Kruskal-Wallis, Chi- square, Mann-Whitney U, Spearman correlation and multiple regression analyses tests. Results: Serum Ucn-2 levels were decreased in Group A and were increased in Group B compared to Group C (9.4±3.4, 12.8±3.6 vs. 10.4±3.9 pg/ mL, respectively, p=0.003). Unlike SD; there was no significant difference in serum Ucn-2 levels between subjects with and without DD (11.4±4.1 vs 11.7±3.9 pg/mL, p=0.8) or CAD (10.7±4.7 vs 10.2±3.2 pg/mL, p=0.7). Conclusion: Ucn-2 is elevated in mild to moderate SD. But, DD (impaired relaxation pattern), or CAD (without myocardial infarction) seems to have no effect on Ucn-2 hormone levels.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995: 378; 287-92. [CrossRef]
2. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001; 27: 2843-8. [CrossRef]
3. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001; 19: 7570-5. [CrossRef]
4. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23: 71-7. [CrossRef]
5. Iino K, Sasano H, Oki Y, Andoh N, Shin RW, Kitamoto T, et al. Urocortin expression in the human central nervous system. Clin Endocrinol 1999; 50: 107-14. [CrossRef]
6. Baigent SM, Lowry PJ. mRNA expression profiles for corticotrophin- releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 2000; 25: 43-52. [CrossRef]
7. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002; 87: 340-6. [CrossRef]
8. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997; 272: H2115-22.
9. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001; 169: 177-83. [CrossRef]
10. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000; 275: 8508-14. [CrossRef]
11. Barry SP Lawrence KM, McCormick J, Soond SM, Hubank M, Eaton S, et al. New targets of urocortin-mediated cardioprotection. J Mol Endocrinol 2010; 45: 69-85. [CrossRef]
12. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal and renal effects in experimental heart failure. Eur Heart J 2005; 26: 2055-62. [CrossRef]
13. Gu Y, Zhang K, Biswas N, Friese RS, Lin DH, Mahata SK, et al. Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity. Endocrinology 2010; 151: 4820-9. [CrossRef]
14. Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004; 10: 490-5. [CrossRef]
15. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007; 28: 2589-97. [CrossRef]
16. Dieterle T, Meili-Butz S, Bühler K, Morandi C, John D, Buser PT, et al. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? Hypertension 2009; 53: 739-44. [CrossRef]
17. Rademaker MT, Charles CJ, Nicholls G, Richards M. Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure. J Hypertens 2011; 29: 1787-95. [CrossRef]
18. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004; 106: 383-8. [CrossRef]
19. Wright SP Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. Plasma urocortin 1 in human heart failure. Circ Heart Fail 2009; 2: 465-71. [CrossRef]
20. Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Circulating levels of stress associated peptide Urocortin in heart failure patients. Peptides 2010; 31: 354-6. [CrossRef]
21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-63. [CrossRef]
22. Nagueh SF, Appleton CP Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22: 107-33. [CrossRef]
23. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004; 17: 290-7. [CrossRef]
24. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59. [CrossRef]
25. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24. [CrossRef]
26. Daniels LB, Clopton P Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010; 160: 721-8. [CrossRef]
27. Agnello D, Bertini R, Sacco S, Meazza C, Villa P Ghezzi P Corticosteroid- independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 1998; 275: E757-62.
28. Yuan Z, McCauley R, Chen-Scarabelli C, Abounit K, Stephanou A, Barry SP et al. Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection. Mol Cell Endocrinol 2010; 325: 1-7. [CrossRef]
29. Tang WH, Shrestha K, Martin MG, Borowski AG, Jasper S, Yandle TG, et al. Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure. J Card Fail 2010; 16: 635-40. [CrossRef]
30. Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S, Chattipakorn N. Plasma urocortin in acute myocardial infarction patients. Eur J Clin Invest 2010; 40: 874-82. [CrossRef]

APA	TOPAL E, YAĞMUR J, Otlu B, ATAŞ H, CANSEL M, AÇIKGÖZ N, ERMİŞ N (2012). Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. , 115 - 120.
Chicago	TOPAL Ergün,YAĞMUR Jülide,Otlu Baris,ATAŞ Halil,CANSEL MEHMET,AÇIKGÖZ Nusret,ERMİŞ Necip Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. (2012): 115 - 120.
MLA	TOPAL Ergün,YAĞMUR Jülide,Otlu Baris,ATAŞ Halil,CANSEL MEHMET,AÇIKGÖZ Nusret,ERMİŞ Necip Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. , 2012, ss.115 - 120.
AMA	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. . 2012; 115 - 120.
Vancouver	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. . 2012; 115 - 120.
IEEE	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N "Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study." , ss.115 - 120, 2012.
ISNAD	TOPAL, Ergün vd. "Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study". (2012), 115-120.

APA	TOPAL E, YAĞMUR J, Otlu B, ATAŞ H, CANSEL M, AÇIKGÖZ N, ERMİŞ N (2012). Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. Anadolu Kardiyoloji Dergisi, 12(2), 115 - 120.
Chicago	TOPAL Ergün,YAĞMUR Jülide,Otlu Baris,ATAŞ Halil,CANSEL MEHMET,AÇIKGÖZ Nusret,ERMİŞ Necip Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. Anadolu Kardiyoloji Dergisi 12, no.2 (2012): 115 - 120.
MLA	TOPAL Ergün,YAĞMUR Jülide,Otlu Baris,ATAŞ Halil,CANSEL MEHMET,AÇIKGÖZ Nusret,ERMİŞ Necip Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. Anadolu Kardiyoloji Dergisi, vol.12, no.2, 2012, ss.115 - 120.
AMA	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. Anadolu Kardiyoloji Dergisi. 2012; 12(2): 115 - 120.
Vancouver	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study. Anadolu Kardiyoloji Dergisi. 2012; 12(2): 115 - 120.
IEEE	TOPAL E,YAĞMUR J,Otlu B,ATAŞ H,CANSEL M,AÇIKGÖZ N,ERMİŞ N "Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study." Anadolu Kardiyoloji Dergisi, 12, ss.115 - 120, 2012.
ISNAD	TOPAL, Ergün vd. "Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study". Anadolu Kardiyoloji Dergisi 12/2 (2012), 115-120.